Skip to main content

FETAL VALPROATE SYNDROME

EDM (Early Day Motion) 9: tabled on 08 May 2013

Tabled in the 2013-14 session.

This motion has been signed by 28 Members. It has not yet had any amendments submitted.

As this motion is using historical data, we may not have the record of the original ordering, in which case signatories are listed alphabetically.

Motion text

That this House notes with concern the recent refusal by the Minister for Care and Support of a public inquiry into why information was withheld concerning the disastrous way in which sodium valproate has affected pregnant women and their children; further notes the cost to the public purse of additional health, education and welfare costs incurred by families affected by Fetal Valproate Syndrome; believes that the regulator could have avoided such costs and large numbers of people affected since sodium valproate was licensed and sold from 1973; further believes that its makers, the pharmaceutical company Sanofi, failed in its duty of care and corporate responsibility by not informing the relevant agencies of its teratogenic effects; welcomes the Minister's recent decision to meet representatives of the Independent Fetal Anti-Convulsant Trust; and urges the holding of a public inquiry.

The first 6 Members who have signed to support the motion are the sponsors. The primary sponsor is generally the person who tabled the motion and has responsibility for it. The date shown is when the Member signed the motion.

In addition to the sponsors, the following Members have signed to support the motion.

There are no withdrawn signatures for this motion.